Retevmo Approved for RET-Driven Solid Tumors, NSCLC
The approvals were based on data from the LIBRETTO-001 trial.
Pancreatic/Thyroid/Other Endocrine Cancers
Sugar-Sweetened Drink Intake Linked to Mortality From Some Cancers
SSBs associated with increased mortality for colorectal, kidney cancers, even after adjustment for BMI
Cancer Risk Higher for Men vs Women at Most Shared Anatomic Sites
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11 percent
Coffee Does Not Impede Bioavailability of LT4 Solution
Bioavailability is equivalent for levothyroxine oral solution administered five minutes prior to coffee or under fasting conditions
Fecal Microbiota-Based Screening Feasible for Pancreatic Cancer
Fecal metagenomics classifiers better than salivary-based classifiers for identifying pancreatic ductal adenocarcinoma
Cabometyx Approved for Radioactive Iodine-Refractory Differentiated Thyroid Cancer
The approval was based on data from the phase 3 COSMIC-311 study.
Jemperli Gets Accelerated Approval for dMMR Recurrent or Advanced Solid Tumors
The accelerated approval was based on data from the phase 1 GARNET trial.
FDA to Review Cabozantinib for Differentiated Thyroid Cancer
The sNDA is supported by data from the phase 3 COSMIC-311 study.
ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
Evidence-based guidelines address diagnosis, evaluation, and treatment, including early multidisciplinary care team involvement
FDA-Approved VEGFR Tyrosine Kinase Inhibitors Ranked by Cardiotoxic Potential
Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.
